Anne-Vibeke Lænkholm

Research output

Research output per year 2013 2018 2019

• 28 Journal article
• 1 Comment/debate
• 1 Conference abstract in journal
• 1 Editorial

Research output per year

Research output per year

Search results

• 2019

  Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

  Sønderstrup, I. M. H., Jensen, M. B., Ejlertsen, B., Eriksen, J. O., Gerdes, A. M., Kruse, T. A., Larsen, M. J., Thomassen, M. & Lænkholm, A. V., 4 Mar 2019, In: Acta Oncologica. 58, 3, p. 363-370 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Breast Neoplasms 50%
  • Mutation 11%
  • Germ-Line Mutation 7%
  • Survival 7%
  8 Citations (Scopus)
• 2018

  An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG)

  Laenkholm, A-V., Grabau, D., Talman, M-L. M., Balslev, E., Bak Jylling, A. M., Tabor, T. P., Johansen, M., Brügmann, A., Lelkaitis, G., Di Caterino, T., Mygind, H., Poulsen, T., Mertz, H., Søndergaard, G. & Rasmussen, B. B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 83-89 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Pathology 99%
  • Light 20%
  • Observer Variation 16%
  • Pathologists 13%
  19 Citations (Scopus)

• Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG

  Soenderstrup, I. M. H., Laenkholm, A. V., Jensen, M. B., Eriksen, J. O., Gerdes, A. M., Hansen, T. V. O., Kruse, T. A., Larsen, M. J., Pedersen, I. S., Rossing, M., Thomassen, M. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 95-101

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Disease-Free Survival 45%
  • Mastectomy 26%
  • Neoplasms 23%
  • Mutation 20%
  9 Citations (Scopus)

• Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer

  Kodahl, A. R., Ehmsen, S., Pallisgaard, N., Jylling, A. M. B., Jensen, J. D., Laenkholm, A., Knoop, A. S. & Ditzel, H. J., Jun 2018, In: Molecular Oncology. 12, 6, p. 925-935 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Circulating Tumor DNA 100%
  • Breast Neoplasms 44%
  • Mutation 34%
  • Serum 23%
  • Liquid Biopsy 12%
  24 Citations (Scopus)

  24 Downloads (Pure)

• Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression

  Krøigård, A. B., Larsen, M. J., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Thomassen, M. & Kruse, T. A., Jan 2018, In: PLoS ONE. 13, 1, 18 p., e0189887.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Metastasis 100%
  • neoplasm progression 98%
  • Driver 85%
  • metastasis 83%
  • Breast Cancer 81%
  13 Citations (Scopus)

  27 Downloads (Pure)

• Is DBCG abreast of new developments?

  Offersen, B. V., Ejlertsen, B., Balslev, E., Flyger, H., Gerdes, A-M., Hansen, M. K., Hølmich, L. R., Jensen, M-B., Kristensen, B., Lænkholm, A-V., Mouridsen, H. T., Nielsen, M. H., Overgaard, J., Tuxen, M., Vejborg, I. & Christiansen, P., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 1-2 2 p.

  Research output: Contribution to journal › Editorial

  1 Citation (Scopus)

• Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

  Jensen, M. B., Nielsen, T. O., Knoop, A. S., Laenkholm, A. V., Balslev, E. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 135-140

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Recurrence 89%
  • Mortality 78%
  • Statistical Models 29%
  • Neoplasms 25%
  2 Citations (Scopus)

• Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG)

  Skriver, S. K., Lænkholm, A-V., Rasmussen, B. B., Handler, J., Grundtmann, B., Tvedskov, T. F., Christiansen, P., Knoop, A. S., Jensen, M-B. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 31-37 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Letrozole 100%
  • Estrogen Receptors 67%
  • Breast Neoplasms 46%
  • Neoadjuvant Therapy 37%
  • Aromatase Inhibitors 9%
  5 Citations (Scopus)

• PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

  Lænkholm, A-V., Jensen, M-B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., Nielsen, T. O., Haffner, T., Kibøl, T., Møller Talman, M-L., Bak Jylling, A. M., Tabor, T. P. & Ejlertsen, B., 10 Mar 2018, In: Journal of Clinical Oncology. 36, 8, p. 735-740

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Hormones 100%
  • Breast Neoplasms 90%
  • Recurrence 81%
  • Confidence Intervals 33%
  • Therapeutics 23%
  47 Citations (Scopus)

• Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008–2017

  Mouridsen, H., Christiansen, P., Jensen, M. B., Lænkholm, A-V., Flyger, H., Offersen, B., Vejborg, I. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 154-156 3 p.

  Research output: Contribution to journal › Comment/debate › Research

• Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists

  Tramm, T., Di Caterino, T., Jylling, A. M. B., Lelkaitis, G., Lænkholm, A. V., Ragó, P., Tabor, T. P., Talman, M. L. M., Vouza, E. & On behalf of the Scientific Committee of Pathology, Danish Breast Cancer Group (DBCG), 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 90-94

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Pathologists 77%
  • Breast Neoplasms 50%
  • Evaluation Studies 5%
  • Histology 4%
  12 Citations (Scopus)

• The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes

  Lænkholm, A-V., Jensen, M-B., Eriksen, J. O., Buckingham, W., Ferree, S., Nielsen, T. O. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 44-50

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ductal Carcinoma 100%
  • Hormones 86%
  • Recurrence 70%
  • Breast Neoplasms 43%
  • human ERBB2 protein 33%
  5 Citations (Scopus)

• The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016

  Jensen, M. B., Laenkholm, A. V., Offersen, B. V., Christiansen, P., Kroman, N., Mouridsen, H. T. & Ejlertsen, B., 2 Jan 2018, In: Acta Oncologica. 57, 1, p. 13-18

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Guidelines 100%
  • Breast Neoplasms 99%
  • Databases 93%
  • Therapeutics 25%
  • Segmental Mastectomy 19%
  28 Citations (Scopus)

• The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

  Jensen, M-B., Lænkholm, A-V., Nielsen, T. O., Eriksen, J. O., Wehn, P., Hood, T., Ram, N., Buckingham, W., Ferree, S. & Ejlertsen, B., 27 Jul 2018, In: Breast cancer research : BCR. 20, 10 p., 79.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cyclophosphamide 100%
  • Breast Neoplasms 68%
  • Gene Expression 64%
  • Drug Therapy 63%
  • Methotrexate 41%
  19 Citations (Scopus)

  19 Downloads (Pure)

• Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D3

  Lundqvist, J., Kirkegaard, T., Laenkholm, A-V., Duun-Henriksen, A. K., Bak, M., Feldman, D. & Lykkesfeldt, A. E., Mar 2018, In: The Journal of Steroid Biochemistry and Molecular Biology. 177, p. 171-178

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Williams Syndrome 100%
  • Calcitriol 82%
  • Estrogen 75%
  • Estrogen Receptors 66%
  • Transcription Factors 53%
  5 Citations (Scopus)
• 2017

  Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer

  Holten-Rossing, H., Talman, M-L. M., Jylling, A. M. B., Laenkholm, A-V., Kristensson, M. & Vainer, B., Dec 2017, In: Histopathology. 71, 6, p. 866-873

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Sentinel Lymph Node Biopsy 100%
  • Workload 79%
  • Breast Neoplasms 50%
  • University Hospitals 35%
  • Biopsy 34%
  17 Citations (Scopus)

• Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence

  Krøigård, A. B., Larsen, M. J., Brasch-Andersen, C., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Thomassen, M. & Kruse, T. A., 9 Mar 2017, In: Scientific Reports. 7, 9 p., 43813.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Breast Neoplasms 100%
  • Neoplasm Metastasis 96%
  • Neoplasms 40%
  • Whole Exome Sequencing 37%
  • High-Throughput Nucleotide Sequencing 30%
  11 Citations (Scopus)

  54 Downloads (Pure)

• Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  Milne, R. L., Kuchenbaecker, K. B., Michailidou, K., Beesley, J., Kar, S., Lindström, S., Hui, S., Lemaçon, A., Soucy, P., Dennis, J., Jiang, X., Rostamianfar, A., Finucane, H., Bolla, M. K., McGuffog, L., Wang, Q., Aalfs, C. M., ABCTB Investigators, Adams, M., Adlard, J., & 27 othersAgata, S., Ahmed, S., Ahsan, H., Aittomäki, K., Al-Ejeh, F., Allen, J., Ambrosone, C. B., Amos, C. I., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Arnold, N., Aronson, K. J., Auber, B., Auer, P. L., Ausems, M. G. E. M., Azzollini, J., Bacot, F., Balmaña, J., Bojesen, S. E., Gerdes, A-M., Lænkholm, A-V., Nordestgaard, B. G., Schmidt, M. K., Antoniou, A. C. & Simard, J., 1 Dec 2017, In: Nature Genetics. 49, 12, p. 1767-1778

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Estrogen Receptors 100%
  • Breast Neoplasms 68%
  • Genome-Wide Association Study 55%
  • Mutation 29%
  • Familial Breast Cancer 25%
  118 Citations (Scopus)
• 2016

  Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data

  Krøigård, A. B., Thomassen, M., Lænkholm, A-V., Kruse, T. A. & Larsen, M. J., Mar 2016, In: PloS one. 11, 3, 15 p., e0151664.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • somatic mutation 100%
  • Exome 89%
  • Sequencing 89%
  • high-throughput nucleotide sequencing 88%
  • mutation 74%
  80 Citations (Scopus)

• Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study

  Erichsen, R., Kelsh, M. A., Oliner, K. S., Nielsen, K. B., Frøslev, T., Lænkholm, A-V., Vyberg, M., Acquavella, J. & Sørensen, H. T., Jul 2016, In: Annals of Epidemiology. 26, 7, p. 500-3 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Epithelial-Mesenchymal Transition 100%
  • Stomach Neoplasms 83%
  • Cohort Studies 65%
  • Neoplasms 31%
  • Confidence Intervals 11%
  3 Citations (Scopus)

• Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET)

  Eriksen, J. O., Jensen, M-B., Laenkholm, A-V., Kibøll, T., Rasmussen, B. B., Knoop, A. S., Ferree, S., Haffner, T., Buckingham, W., Schaper, C. & Ejlertsen, B., 2016, In: Cancer Research. 76, 4 Supplement, 1 p., P2-08-10.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
• 2015

  An international study to increase concordance in Ki67 scoring

  Polley, M-Y. C., Leung, S. C. Y., Gao, D., Mastropasqua, M. G., Zabaglo, L. A., Bartlett, J. M. S., McShane, L. M., Enos, R. A., Badve, S. S., Bane, A. L., Borgquist, S., Fineberg, S., Lin, M-G., Gown, A. M., Grabau, D., Gutierrez, C., Hugh, J. C., Moriya, T., Ohi, Y., Osborne, C. K., & 11 othersPenault-Llorca, F. M., Piper, T., Porter, P. L., Sakatani, T., Salgado, R., Starczynski, J., Lænkholm, A-V., Viale, G., Dowsett, M., Hayes, D. F. & Nielsen, T. O., 1 Jun 2015, In: Modern Pathology. 28, 6, p. 778-86 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Research Design 100%
  • Calibration 86%
  • Biomarkers 54%
  • Staining and Labeling 54%
  • Software 31%
  145 Citations (Scopus)

• Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer

  Larsen, S. L., Yde, C. W., Laenkholm, A-V., Rasmussen, B. B., Duun-Henriksen, A. K., Bak, M., Lykkesfeldt, A. E. & Kirkegaard, T., 8 Apr 2015, In: B M C Cancer. 15, 15 p., 239.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Aurora Kinase B 100%
  • Estrogen Receptor Modulators 83%
  • Tamoxifen 69%
  • 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate 61%
  • Fulvestrant 54%
  18 Citations (Scopus)

• Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis

  Krøigård, A. B., Larsen, M. J., Lænkholm, A-V., Knoop, A. S., Jensen, J. D., Bak, M., Mollenhauer, J., Kruse, T. A. & Thomassen, M., 2015, In: OncoTarget. 6, 8, p. 5634-49 16 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Genome 100%
  • Breast Neoplasms 93%
  • Neoplasm Metastasis 90%
  • Neoplasms 47%
  • Exome 29%
  28 Citations (Scopus)

• Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

  Thomsen, K. G., Lyng, M. B., Elias, D., Vever, H., Knoop, A. S., Lykkesfeldt, A. E., Lænkholm, A-V. & Ditzel, H. J., 1 Dec 2015, In: Breast Cancer Research and Treatment. 154, 3, p. 483-94 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Aromatase Inhibitors 100%
  • Breast Neoplasms 51%
  • Gene Expression 48%
  • exemestane 45%
  • Growth 30%
  7 Citations (Scopus)

• NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer

  Lund, R. R., Leth-Larsen, R., Caterino, T. D., Terp, M. G., Nissen, J., Lænkholm, A-V., Jensen, O. N. & Ditzel, H. J., Nov 2015, In: Molecular and Cellular Proteomics. 14, 11, p. 2988-99 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • rat Cyb5R3 protein 100%
  • Cytochrome B5 62%
  • Cytochrome Reductases 58%
  • Cytochromes b5 55%
  • Estrogen 49%
  11 Citations (Scopus)

• SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment

  Larsen, S. L., Laenkholm, A-V., Duun-Henriksen, A. K., Bak, M., Lykkesfeldt, A. E. & Kirkegaard, T., 23 Feb 2015, In: PloS one. 10, 2, e0118346.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • tamoxifen 100%
  • Estrogen Receptor Modulators 93%
  • Breast Cancer 90%
  • breast neoplasms 83%
  • Tamoxifen 77%
  18 Citations (Scopus)
• 2014

  Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial

  Knoop, A. S., Lænkholm, A-V., Jensen, M-B., Nielsen, K. V., Andersen, J., Nielsen, D., Ejlertsen, B. & Danish Breast Cancer Cooperative Group, May 2014, In: European journal of cancer (Oxford, England : 1990). 50, 8, p. 1412-1421 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tamoxifen 100%
  • Progesterone Receptors 99%
  • Estrogen Receptors 88%
  • Breast Neoplasms 60%
  • Recurrence 14%
  20 Citations (Scopus)

• RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families

  Larsen, M. J., Thomassen, M., Tan, Q., Lænkholm, A-V., Bak, M., Sørensen, K. P., Andersen, M. K., Kruse, T. A. & Gerdes, A-M., 31 Jan 2014, In: B M C Medical Genomics. 7, p. 9

  Research output: Contribution to journal › Journal article › Research › peer-review

  • RNA 100%
  • Breast Neoplasms 92%
  • Neoplasms 21%
  • Biopsy 13%
  • Phenotype 13%
  12 Citations (Scopus)
• 2013

  Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

  Larsen, M. J., Kruse, T. A., Tan, Q., Lænkholm, A-V., Bak, M., Lykkesfeldt, A. E., Sørensen, K. P., Hansen, T. V. O., Ejlertsen, B., Gerdes, A-M. & Thomassen, M., 21 May 2013, In: P L o S One. 8, 5, 12 p., e64268.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Profiling 100%
  • RNA 85%
  • Tumor 75%
  • tumor 74%
  • Tumors 72%
  59 Citations (Scopus)

• Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

  Lyng, M. B., Lænkholm, A-V., Tan, Q., Vach, W., Gravgaard, K. H., Knoop, A. & Ditzel, H., 16 Jan 2013, In: PLOS ONE. 8, 1, p. e54078

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Estrogen Receptor 100%
  • Estrogens 86%
  • tamoxifen 70%
  • Gene Expression 64%
  • Breast Cancer 63%
  11 Citations (Scopus)